D. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Key Points

• D. Boral Capital has reiterated a buy rating for Lineage Cell Therapeutics and set a price target of $2.00, indicating a potential upside of 60% from its last close.
• HC Wainwright also maintains a buy rating with a target price of $9.00, contributing to a consensus price target of $4.25 among analysts.
• Lineage Cell Therapeutics' shares have risen 6.8%, opening at $1.25, with the company demonstrating strong institutional interest as 62.47% of its stock is held by institutional investors.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital's price objective points to a potential upside of 60.00% from the stock's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $4.25.

Lineage Cell Therapeutics Trading Up 6.8%

Shares of Lineage Cell Therapeutics stock opened at $1.25 on Wednesday. The stock has a market capitalization of $285.45 million, a price-to-earnings ratio of -6.94 and a beta of 1.66. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $1.31. The firm's 50-day moving average price is $1.04 and its two-hundred day moving average price is $0.72.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Integrity Alliance LLC. boosted its holdings in shares of Lineage Cell Therapeutics by 75.0% during the 2nd quarter. Integrity Alliance LLC. now owns 35,000 shares of the company's stock worth $32,000 after buying an additional 15,000 shares during the period. Rhumbline Advisers boosted its holdings in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company's stock valued at $91,000 after purchasing an additional 18,092 shares during the period. Barclays PLC boosted its holdings in Lineage Cell Therapeutics by 10.8% in the 4th quarter. Barclays PLC now owns 234,069 shares of the company's stock valued at $118,000 after purchasing an additional 22,769 shares during the period. Wells Fargo & Company MN boosted its holdings in Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company's stock valued at $48,000 after purchasing an additional 23,527 shares during the period. Finally, Kapitalo Investimentos Ltda bought a new stake in Lineage Cell Therapeutics in the 2nd quarter valued at about $25,000. Institutional investors own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.